Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents

Neoplasia

Volumn 8, Issue 6, 2006, Pages 488-498

  Corbin, Ian R ^a   Li, Hui ^a   Chen, Juan ^a   Lund Katzy, Sissel ^b   Zhou, Rong ^a   Glickson, Jerry D ^a   Zheng, Gang ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Human hepatoblastoma G2 (HepG2); Low density lipoprotein (LDL); Low density lipoprotein receptor; Magnetic resonance imaging (MRI); Nanoparticle

Indexed keywords

AMPHOPHILE; CONTRAST MEDIUM; GADODIAMIDE; GADOLINIUM; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NANOPARTICLE; PENTETIC ACID;

AGAR GEL ELECTROPHORESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER DIAGNOSIS; CELL MEMBRANE; CONTROLLED STUDY; ENDOCYTOSIS; HEPATOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; XENOGRAFT;

EID: 33745832274     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.05835     Document Type: Article

References (77)

1. Zoarski GH, Parker JR, Lufkin RB, Harnsberger HR, and Rhoda CH (1992). Efficacy of gadoteridol for magnetic resonance imaging of extracranial head and neck pathology. Invest Radiol 27 (1), S53-S57.
2. Runge VM, Muroff LR, and Jinkins JR (2001). Central nervous system: review of clinical use of contrast media. Top Magn Reson Imaging 12, 231-263.
3. Peterson MS, Baron RL, and Murakami T (1996). Hepatic malignancies: usefulness of acquisition of multiple arterial and portal venous phase images at dynamic gadolinium-enhanced MR imaging. Radiology 201, 337-345.
4. McLachlan SJ, Francisco JC, Pernicone JR, and Hasso AN (1994). Efficacy evaluation of gadoteridol for MR angiography of intracranial vascular lesions. J Magn Reson Imaging 4, 405-411.
5. Ostergaard L (2004). Cerebral perfusion imaging by bolus tracking. Top Magn Reson Imaging 15, 3-9.
6. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, et al. (1999). Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10, 223-232.
7. Aime S, Barge A, Cabella C, Crich SG, and Gianolio E (2004). Targeting cells with MR imaging probes based on paramagnetic Gd(III) chelates. Curr Pharm Biotechnol 5, 509-518.
8. Artemov D, Bhujwalla ZM, and Bulte JW (2004). Magnetic resonance imaging of cell surface receptors using targeted contrast agents. Curr Pharm Biotechnol 5, 485-494.
9. Lanza GM, Winter P, Caruthers S, Schmeider A, Crowder K, Morawski A, Zhang H, Scott MJ, and Wickline SA (2004). Novel paramagnetic contrast agents for molecular imaging and targeted drug delivery. Curr Pharm Biotechnol 5, 495-507.
10. Massoud TF and Gambhir SS (2003). Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17, 545-580.
11. Quintana A, Raczka E, Piehler L, Lee I, Myc A, Majoros I, Patri AK, Thomas T, Mule J, and Baker JR Jr (2002). Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res 19, 1310-1316.
12. Roy I, Ohulchanskyy TY, Pudavar HE, Bergey EJ, Oseroff AR, Morgan J, Dougherty TJ, and Prasad PN (2003). Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. J Am Chem Soc 125, 7860-7865.
13. Kasili PM, Song JM, and Vo-Dinh T (2004). Optical sensor for the detection of caspase-9 activity in a single cell. J Am Chem Soc 126, 2799-2806.
14. Ruoslahti E (2002). Antiangiogenics meet nanotechnology. Cancer Cell 2, 97-98.
15. Anderson SA, Rader RK, Westlin WF, Null C, Jackson D, Lanza GM, Wickline SA, and Kotyk JJ (2000). Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magn Reson Med 44, 433-439.
16. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, and Cheresh DA (2002). Tumor regression by targeted gene delivery to the neovasculature. Science 296, 2404-2407.
17. Schmieder AH, Winter PM, Caruthers SD, Harris TD, Williams TA, Allen JS, Lacy EK, Zhang H, Scott MJ, Hu G, et al. (2005). Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted para-magnetic nanoparticles. Magn Reson Med 53, 621-627.
18. Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, McLean M, Winter P, Sicard GA, Gaffney PJ, Wickline SA, et al. (2001). Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 104, 1280-1285.
19. Kang HW, Josephson L, Petrovsky A, Weissleder R, and Bogdanov A Jr (2002). Magnetic resonance imaging of inducible E-selectin expression in human endothelial cell culture. Bioconjug Chem 13, 122-127.
20. Johansson LO, Bjornerud A, Ahlstrom HK, Ladd DL, and Fujii DK (2001). A targeted contrast agent for magnetic resonance imaging of thrombus: implications of spatial resolution. J Magn Reson Imaging 13, 615-618.
21. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS, Lacy EK, Robertson JD, Lanza GM, et al. (2003). Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 108, 2270-2274.
22. Brown MS and Goldstein JL (1979). Receptor-mediated endocytosis: insights from the lipoprotein receptor system. Proc Natl Acad Sci USA 76, 3330-3337.
23. Chen Y and Hughes-Fulford M (2001). Human prostate cancer cells lack feedback regulation of low-density lipoprotein receptor and its regulator, SREBP2. Int J Cancer 91, 41-45.
24. Tatidis L, Masquelier M, and Vitols S (2002). Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines. Biochem Pharmacol 63, 2169-2180.
25. Peterson C, Vitols S, Rudling M, Blomgren H, Edsmyr F, and Skoog L (1985). Hypocholesterolemia in cancer patients may be caused by elevated LDL receptor activities in malignant cells. Med Oncol Tumor Pharmacother 2, 143-147.
26. Niendorf A, Nagele H, Gerding D, Meyer-Pannwitt U, and Gebhardt A (1995). Increased LDL receptor mRNA expression in colon cancer is correlated with a rise in plasma cholesterol levels after curative surgery. Int J Cancer 61, 461-464.
27. Caruso MG, Notarnicola M, Cavallini A, and Di Leo A (2001). Low density lipoprotein receptor and mRNA expression in human colorectal cancer. Anticancer Res 21, 429-433.
28. Nakagawa T, Ueyama Y, Nozaki S, Yamashita S, Menju M, Funahashi T, Kameda-Takemura K, Kubo M, Tokunaga K, Tanaka T, et al. (1995). Marked hypocholesterolemia in a case with adrenal adenoma - enhanced catabolism of low density lipoprotein (LDL) via the LDL receptors of tumor cells. J Clin Endocrinol Metab 80, 92-96.
29. Graziani SR, Igreja FA, Hegg R, Meneghetti C, Brandizzi LI, Barboza R, Amancio RF, Pinotti JA, and Maranhao RC (2002). Uptake of a cholesterol-rich emulsion by breast cancer. Gynecol Oncol 85, 493-497.
30. Stranzl A, Schmidt H, Winkler R, and Kostner GM (1997). Low-density lipoprotein receptor mRNA in human breast cancer cells: influence by PKC modulators. Breast Cancer Res Treat 42, 195-205.
31. Masquelier M, Vitols S, and Peterson C (1986). Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice. Cancer Res 46, 3842-3847.
32. Lees AM and Lees RS (1991). 99mTechnetium-labeled low density lipoprotein: receptor recognition and intracellular sequestration of radio-label. J Lipid Res 32, 1-8.
33. Moerlein SM, Daugherty A, Sobel BE, and Welch MJ (1991). Metabolic imaging with gallium-68- and indium-111-labeled low-density lipoprotein. J Nucl Med 32, 300-307.
34. Jasanada F, Urizzi P, Souchard JP, Le Gaillard F, Favre G, and Nepveu F (1996). Indium-111 labeling of low density lipoproteins with the DTPA-bis(stearylamide): evaluation as a potential radiopharmaceutical for tumor localization. Bioconjug Chem 7, 72-81.
35. Urizzi P, Souchard JP, Palevody C, Ratovo G, Hollande E, and Nepveu F (1997). Internalization of indium-labeled LDL through a lipid chelating anchor in human pancreatic-cancer cells as a potential radiopharmaceutical for tumor localization. Int J Cancer 70, 315-322.
36. Li H, Zhang Z, Blessington D, Nelson DS, Zhou R, Lund-Katz S, Chance B, Glickson JD, and Zheng G (2004). Carbocyanine labeled LDL for optical imaging of tumors. Acad Radiol 11, 669-677.
37. Zheng G, Li H, Yang K, Blessington D, Licha K, Lund-Katz S, Chance B, and Glickson JD (2002). Tricarbocyanine cholesteryl laurates labeled LDL: new near infrared fluorescent probes (NIRFs) for monitoring tumors and gene therapy of familial hypercholesterolemia. Bioorg Med Chem Lett 12, 1485-1488.
38. Ponty E, Favre G, Benaniba R, Boneu A, Lucot H, Carton M, and Soula G (1993). Biodistribution study of 99mTc-labeled LDL in B16-melanoma-bearing mice. Visualization of a preferential uptake by the tumor. Int J Cancer 54, 411-417.
39. Li H, Gray BD, Corbin I, Lebherz C, Choi H, Lund-Katz S, Wilson JM, Glickson JD, and Zhou R (2004). MR and fluorescent imaging of low-density lipoprotein receptors. Acad Radiol 11, 1251-1259.
40. Lund-Katz S, Laplaud PM, Phillips MC, and Chapman MJ (1998). Apo-lipoprotein B-100 conformation and particle surface charge in human LDL subspecies: implication for LDL receptor interaction. Biochemistry 37, 12867-12874.
41. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, and Krieger M (1996). Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271, 518-520.
42. Krieger M (1986). Reconstitution of the hydrophobic core of low-density-lipoprotein. Methods Enzymol 128, 608-613.
43. Pitas RE, Boyles J, Mahley RW, and Bissell DM (1985). Uptake of chemically modified low density lipoproteins in vivo is mediated by specific endothelial cells. J Cell Biol 100, 103-117.
44. Lund-Katz S, Ibdah JA, Letizia JY, Thomas MT, and Phillips MC (1988). A 13C NMR characterization of lysine residues in apolipoprotein B and their role in binding to the low density lipoprotein receptor. J Biol Chem 263, 13831-13838.
45. Lautt WW and Macedo MP (1997). Hepatic circulation and toxicology. Drug Metab Rev 29, 369-395.
46. Frias JC, Williams KJ, Fisher EA, and Fayad ZA (2004). Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc 126, 16316-16317.
47. Glogard C, Stensrud G, Hovland R, Fossheim SL, and Klaveness J (2002). Liposomes as carriers of amphiphilic gadolinium chelates: the effect of membrane composition on incorporation efficacy and in vitro relaxivity. Int J Pharm 233, 131-140.
48. Hovland R, Glogard C, Aasen AJ, and Klaveness J (2003). Preparation and in vitro evaluation of a novel amphiphilic GdPCTA-[12] derivative; a micellar MRI contrast agent. Org Biomol Chem 1, 644-647.
49. Winter PM, Caruthers SD, Yu X, Song SK, Chen J, Miller B, Bulte JW, Robertson JD, Gaffney PJ, Wickline SA, et al. (2003). Improved molecular imaging contrast agent for detection of human thrombus. Magn Reson Med 50, 411-416.
50. Tilcock C, Ahkong QF, Koenig SH, Brown RD III, Davis M, and Kabalka G (1992). The design of liposomal paramagnetic MR agents: effect of vesicle size upon the relaxivity of surface-incorporated lipophilic chelates. Magn Reson Med 27, 44-51.
51. Segrest JP, Jones MK, De Loof H, and Dashti N (2001). Structure of apolipoprotein B-100 in low density lipoproteins. J Lipid Res 42, 1346-1367.
52. Muller RN, Raduchel B, Laurent S, Platzek J, Pierart C, Mareski P, and Vander Elst L (1999). Physicochemical characterization of MS-325, a new gadolinium complex, by multinuclear relaxometry. Eur J Inorg Chem, 1949-1955.
53. Aime S, Botta M, Geninatti Crich S, Giovenzana GB, Pagliarin R, Piccinini M, Sisti M, and Terreno E (1997). Towards MRI contrast agents of improved efficacy. NMR relaxometric investigations of the binding interaction to HSA of a novel heptadentate macrocyclic triphosphonate Gd(III)-complex. J Biol Inorg Chem 2, 470-479.
54. Aime S, Chiaussa M, Digilio G, Gianolio E, and Terreno E (1999). Contrast agents for magnetic resonance angiographic applications: 1H and 17O NMR relaxometric investigations of two gadolinium (III) DTPA-like chelates endowed with high binding affinity to human serum albumin. J Biol Inorg Chem 4, 766-774.
55. Brown MS and Goldstein JL (1975). Regulation of the activity of the low density lipoprotein receptor in human fibroblasts. Cell 6, 307-316.
56. Rhainds D and Brissette L (1999). Low density lipoprotein uptake: holoparticle and cholesteryl ester selective uptake. Int J Biochem Cell Biol 31, 915-931.
57. Brissette L, Charest MC, and Falstrault L (1996). Selective uptake of cholesteryl esters of low-density lipoproteins is mediated by the lipoprotein-binding site in HepG2 cells and is followed by the hydrolysis of cholesteryl esters. Biochem J 318 (Pt 3), 841-847.
58. Calvo D, Gomez-Coronado D, Suarez Y, Lasuncion MA, and Vega MA (1998). Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. J Lipid Res 39, 777-788.
59. Acton SL, Scherer PE, Lodish HF, and Krieger M (1994). Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J Biol Chem 269, 21003-21009.
60. Mitsumori LM, Ricks JL, Rosenfeld ME, Schmiedl UP, and Yuan C (2004). Development of a lipoprotein based molecular imaging MR contrast agent for the noninvasive detection of early atherosclerotic disease. Int J Cardiovasc Imaging 20, 561-567.
61. Kobayashi K, Oka K, Forte T, Ishida B, Teng B, Ishimura-Oka K, Nakamuta M, and Chan L (1996). Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirusmediated gene transfer of the very low density lipoprotein receptor. J Biol Chem 271, 6852-6860.
62. Isaacsohn JL, Lees AM, Lees RS, Strauss HW, Barlai-Kovach M, and Moore TJ (1986). Adrenal imaging with technetium-99m-labelled low density lipoproteins. Metabolism 35, 364-366.
63. Li H, Marotta DE, Kim S, Busch TM, Wileyto EP, and Zheng G (2005). High payload delivery of optical imaging and photodynamic therapy agents to tumors using phthalocyanine-reconstituted low-density lipoprotein nanoparticles. J Biomed Opt 10, 41203.
64. Filipowska D, Filipowski T, Morelowska B, Kazanowska W, Laudanski T, Lapinjoki S, Akerlund M, and Breeze A (1992). Treatment of cancer patients with a low-density-lipoprotein delivery vehicle containing a cytotoxic drug. Cancer Chemother Pharmacol 29, 396-400.
65. Firestone RA (1994). Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjug Chem 5, 105-113.
66. De Smidt PC, Bijsterbosch MK, and Van Berkel TJ (1990). LDL as a carrier in site-specific drug delivery. Targeted Diagn Ther 3, 355-383.
67. Kader A and Pater A (2002). Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells. J Control Release 80, 29-44.
68. Bijsterbosch MK, van de Bilt H, and van Berkel TJ (1996). Specific targeting of a lipophilic prodrug of iododeoxyuridine to parenchymal liver cells using lactosylated reconstituted high density lipoprotein particles. Biochem Pharmacol 52, 113-121.
69. Bijsterbosch MK, Ying C, de Vrueh RL, de Clercq E, Biessen EA, Neyts J, and van Berkel TJ (2001). Carrier-mediated delivery improves the efficacy of 9-(2-phosphonylmethoxyethyl)adenine against hepatitis B virus. Mol Pharmacol 60, 521-527.
70. Gal D, Ohashi M, MacDonald PC, Buchsbaum HJ, and Simpson ER (1981). Low-density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms. Am J Obstet Gynecol 139, 877-885.
71. Masquelier M, Tirzitis G, Peterson CO, Palsson M, Amolins A, Plotniece M, Plotniece A, Makarova N, and Vitols SG (2000). Plasma stability and cytotoxicity of lipophilic daunorubicin derivatives incorporated into low density lipoproteins. Eur J Med Chem 35, 429-438.
72. Masquelier M, Vitols S, Palsson M, Mars U, Larsson BS, and Peterson CO (2000). Low density lipoprotein as a carrier of cytostatics in cancer chemotherapy: study of stability of drug-carrier complexes in blood. J Drug Target 8, 155-164.
73. Yanovich S, Preston L, and Shaw JM (1984). Characteristics of uptake and cytotoxicity of a low-density lipoprotein-daunomycin complex in P388 leukemic cells. Cancer Res 44, 3377-3382.
74. Zheng G, Chen J, Li H, and Glickson JD (2005). Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc Natl Acad Sci USA 102, 17757-17762.
75. Todorovska A, Roovers RC, Dolezal O, Kortt AA, Hoogenboom HR, and Hudson PJ (2001). Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods 248, 47-66.
76. Stefanidakis M and Koivunen E (2004). Peptide-mediated delivery of therapeutic and imaging agents into mammalian cells. Curr Pharm Des 10, 3033-3044.
77. Dyba M, Tarasova NI, and Michejda CJ (2004). Small molecule toxins targeting tumor receptors. Curr Pharm Des 10, 2311-2334.